Kendra Wilkinson has shared what prompted her to join the growing list of celebrities turning to GLP-1 medications.
Drugs such as semaglutide (marketed as Ozempic and Wegovy) and tirzepatide (often referred to as Mounjaro) were initially approved to help manage diabetes.
They work by influencing how the pancreas releases insulin, and they can also curb appetite by making people feel full sooner during meals.
In recent years, these treatments have become increasingly associated with weight management as well, particularly among high-profile figures.
Wilkinson, now 40, says she plans to begin a GLP-1 medication this year and discussed the decision and her approach to fitness in a new interview.
“There’s nothing worse than being in a gym every single day, working out and not seeing any progress,” she told US Weekly. “I hit 40. I’m happy. I’m at peace, but I noticed that my jeans are a little tighter lately, so I don’t want to go out and shop anymore. Mama is on a budget, so I have to fit back in my jeans… So I’ll start my journey next week.”
She also emphasized that she wants to take a gradual, steady approach rather than chasing drastic results. “I just want to be balanced out,” she added. “I don’t really want to be skinny, but I just want to be balanced and fit in my jeans again.
“Look, I’m a little bit overweight at the moment, so I’m gonna start taking my weight loss shots,” she continued. “I’m starting that journey next week. But other than that, just get out and play. You know, it’s beautiful out in life.”
Her comments come amid broader public interest in GLP-1 medications. A report released last year found that one in eight Americans had used GLP-1 drugs specifically for weight loss, and 14 percent said they were interested in trying them.
The same RAND report noted that prescriptions for GLP-1 medications have surged since 2020, with the total number more than tripling.
At the same time, medical professionals have urged caution, particularly for those viewing the drugs as a rapid solution, as research continues to examine potential downsides and side effects.
One recent study from the University of Oxford, published in the British Medical Journal, reviewed 37 clinical trials involving more than 9,000 people using semaglutide (Wegovy) or tirzepatide (Mounjaro).
Participants typically stayed on treatment for around 10 months, and researchers followed up for about eight months after that.
According to the findings, many users gained weight back quickly once they stopped the medication, with the rebound occurring faster than what is commonly seen in people losing weight through traditional dieting.